Vericel Corp reports results for the quarter ended March 31 - Earnings Summary

• Vericel Corp VCEL.OQ reported a quarterly adjusted loss of 23 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -8 cents. The mean expectation of eight analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -22 cents to -6 cents per share.

• Revenue rose 2.6% to $52.60 million from a year ago; analysts expected $53.84 million.

• Vericel Corp's reported EPS for the quarter was a loss of 23 cents​.

• The company reported a quarterly loss of $11.25 million.

• Vericel Corp shares had fallen by 9.3% this quarter and lost 26.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 466.4% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Vericel Corp is $64.50

This summary was machine generated from LSEG data May 8 at 02:07 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)